Clinical trials: Benzodiazepine-Related Disorders
COVID-19, ARDS
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
The analgesic and sedation requirements in critically ill patients with COVID-19 have yet to be described. There are various factors that are likely affecting the agents being utilized for analgesia and sedation in these patients…
- Conditions
- COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
- Trial name
- NCT05336656
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Wilkes University
Drug Overdose, Substance Abuse
EEG Monitoring in the Emergency Department
This study seeks to investigate whether drug effects in suspected overdose patients could be identified using the electroencephalogram (EEG).
- Conditions
- Drug Overdose, Substance Abuse, Alcohol Abuse
- Trial name
- NCT04070521
- Testing
- Observational EEG Monitoring
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Alcoholism
Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse
Alcohol-dependence is a medical condition that can lead to the occurrence of an alcohol withdrawal syndrome (AWS) in case of alcohol drinking cessation. Diazepam is the reference medication for preventing or treating AWS.
- Trial name
- DIAMA (NCT02242955)
- Testing
- Diazepam
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Lille
Substance Withdrawal Syndrome
The Effect of Valproate on Benzodiazepine Withdrawal Severity
The aim of this study is to determine whether valproate is effective in the treatment of benzodiazepine withdrawal symptoms in subjects receiving maintenance treatment for opiate dependence.
- Trial name
- NCT00570219
- Testing
- valproate
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- University of Helsinki
Benzodiazepine Withdrawal
Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
We hypothesise that a short-term intervention by dispensing pharmacists is feasible and relatively easy to implement, and that it could have an impact on the deprescribing of BZD/Z in adult patients.
- Trial name
- BENZ_HALTE (NCT06446349)
- Testing
- Brief motivational intervention
- Where
- 20 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Grenoble
Aging, Benzodiazepine Sedative Adverse Reaction
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
Prescribing of potentially unsafe medications for older adults is extremely common; benzodiazepines and sedative hypnotics are, for example, key drug classes frequently implicated in adverse health consequences for vulnerable…
- Conditions
- Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
- Trial name
- NUDGE-EHR (NCT04284553)
- Testing
- Order Entry, Open Encounter, Follow-up booster Alert
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Brigham and Women's Hospital
Substance Use Disorders, Opiate Dependence
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, \& Maguen, 2018) and the Substance Abuse…
- Conditions
- Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder
- Trial name
- NCT03971097
- Testing
- Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Pittsburgh
Opiate Dependence, Drug Dependence
Treatment of Polydrug-Using Opiate Dependents During Withdrawal
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for…
- Conditions
- Opiate Dependence, Drug Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00367874
- Testing
- Buprenorphine, Valproate
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Sorlandet Hospital HF
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Schizophrenia, Schizoaffective Disorder
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- SMART (NCT01431092)
- Testing
- Melatonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Lone Baandrup
Pregnancy Related, Benzodiazepines Causing Adverse Effects in Therapeutic Use
Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy
This is a nationwide cohort study to assess maternal and neonatal outcomes following exposure to benzodiazepines during pregnancy.
- Conditions
- Pregnancy Related, Benzodiazepines Causing Adverse Effects in Therapeutic Use, Congenital Anomaly
- Trial name
- NCT04856436
- Testing
- Benzodiazepine
- Where
- South Korea
- Volunteers
- 3,094,227 people, healthy volunteers welcome
- Sponsor
- Sungkyunkwan University
Benzodiazepine-Related Disorders
Informative Exhibition for Deprescribing Benzodiazepines
The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults.
- Trial name
- ESUB (NCT06467019)
- Testing
- Informative Session
- Where
- Spain
- Volunteers
- 6,410 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Depression - Major Depressive Disorder, Bipolar Disorder (BD)
Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy
The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and/or zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without…
- Conditions
- Depression - Major Depressive Disorder, Bipolar Disorder (BD), Functional Magnetic Resonance Imaging (fMRI), Cognition
- Trial name
- FLEET (NCT07619092)
- Testing
- Flumazenil, Electroconvulsive therapy (ECT)
- Where
- Denmark
- Volunteers
- 145 people
- Sponsor
- Anders Jørgensen
Substance-Related Disorders
Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms
The purpose of this study is to determine if a single dose of pregabalin 300mg in patients receiving medications for sedative-hypnotic withdrawal symptoms will produce meaningful differences in measures of "drug liking" and "drug…
- Trial name
- NCT02423018
- Testing
- Pregabalin
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Centre for Addiction and Mental Health
Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs
Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity
High-potency benzodiazepines have strong anxiolytic effects accompanied by significant adverse effects including impaired cognitive function, drowsiness, dizziness and impaired motoric abilities.
- Trial name
- NCT03829839
- Testing
- Oxytocin, Lorazepam 1 mg
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Panic Disorder, Posttraumatic Stress Disorder
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder
The purpose of this study is to examine how certain brain chemicals work in patients with Panic Disorder (PD) and Post-Traumatic Stress Disorder (PTSD) with and without major depressive disorder (MDD).
- Conditions
- Panic Disorder, Posttraumatic Stress Disorder, Major Depressive Disorder
- Trial name
- NCT00025974
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Elderly, Drug Therapy Syndrome
Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions
Intervention randomized controlled open study with 2 parallel arms . The objective of this study is to evaluate the feasibility of stopping the benzodiazepines treatment in elderly living in nursing homes.
- Conditions
- Elderly, Drug Therapy Syndrome, Substance-Related Disorders, Substance Withdrawal Syndrome
- Trial name
- BenzoFree (NCT02715440)
- Testing
- Immediate intervention
- Volunteers
- 116 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Withdrawal Syndrome, Iatrogenic Disease
AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)
Withdrawal from opioids and sedatives administered for medical purposes (i.e. iatrogenic withdrawal) often goes unrecognized in the critically ill, but its prevalence is high.
- Trial name
- NCT04422808
- Where
- United States
- Volunteers
- 2,437 people
- Sponsor
- Wilkes University
Aging, Benzodiazepine Sedative Adverse Reaction
NUDGE-EHR Replication Trial at Mass General Brigham
Prescribing of potentially unsafe medications for older adults is extremely common; benzodiazepines and sedative hypnotics are, for example, key drug classes frequently implicated in adverse health consequences for vulnerable…
- Conditions
- Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
- Trial name
- NUDGE-EHR (NCT05538065)
- Testing
- Follow-up booster Alert, Pre-commitment, Enhanced Alert
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Brigham and Women's Hospital
Sedative Adverse Reaction, Analgesic Adverse Reaction
The Use of Midazolam and Remifentanil During Dialysis Access Procedures
BACKGROUND: Sedation and analgesia are related to unexpected adverse events in chronic renal failure patients undergoing arteriovenous fistula placement procedures under monitored anesthesia care (MAC).
- Conditions
- Sedative Adverse Reaction, Analgesic Adverse Reaction, Midazolam Adverse Reaction, Adverse Reaction to Drug
- Trial name
- NCT04226443
- Testing
- Midazolam intravenous injection, Remifentanil intravenous bolus dose
- Volunteers
- 99 people
- Sponsor
- Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital